Fenaux Honorine, Ghelfenstein-Ferreira Théo, Salmona Maud, Mahjoub Nadia, Feghoul Linda, Maylin Sarah, Chaix Marie-Laure, Minier Marine, Gabassi Audrey, Goff Jérôme Le, Delaugerre Constance
Laboratoire de virologie, Hôpital Saint Louis -APHP, Paris, France.
Insight U976, team INSIGHT, Université de Paris, Paris, France.
J Clin Virol Plus. 2021 Jun;1(1):100021. doi: 10.1016/j.jcvp.2021.100021. Epub 2021 May 16.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently emerged and is responsible for coronavirus disease 19 (COVID-19). Diagnostic tests have been developed, mainly based on reverse-transcriptase PCR (RT-PCR). Most RT-PCR assays target at least two SARS-CoV-2 genes. In some cases, only one target gene is detected; the interpretation of such cases remains unclear.
Our objective was to analyse one target positive (OPT) RT-PCR results, using two RT-PCR assays: the Xpert® Xpress SARS-CoV-2 (Cepheid diagnosis, "Cepheid") and the Cobas® 6800 SARS-CoV-2 Test (Roche Molecular Diagnostics, "Roche").
All SARS-CoV-2 RT-PCR results performed on respiratory samples with the Roche or the Cepheid tests, from 23rd March to 6th August 2020 were collected. A patient with an OPT result was classified as "probable COVID-19" if they met at least one of the three following criteria: (i) history of a two gene-positive SARS-CoV-2 RT-PCR result, (ii) anti-SARS-CoV-2 antibody (IgG) detection or (iii) compatible chest computed tomography scan (CT-scan).
A total of 18,630 and 1189 SARS-CoV-2 RT-PCR tests were performed with the Roche and Cepheid tests, respectively. Among the positive SARS-CoV-2 RT-PCR, 293 samples - corresponding to 264 patients - were OPT (11% of the positive samples). Of these patients, 180 (68%) had at least one of the three criteria listed above and were classified as probable COVID-19.
Sixty-eight percent of the patients with an OPT result were classified as probable COVID-19 and are probably at a late stage of infection. Serology and imaging can be helpful to confirm diagnosis.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)最近出现,是冠状病毒病19(COVID-19)的病原体。诊断测试已经开发出来,主要基于逆转录酶聚合酶链反应(RT-PCR)。大多数RT-PCR检测针对至少两个SARS-CoV-2基因。在某些情况下,仅检测到一个靶基因;此类情况的解读仍不明确。
我们的目的是使用两种RT-PCR检测方法分析单靶标阳性(OPT)RT-PCR结果:Xpert® Xpress SARS-CoV-2(赛沛诊断,“赛沛”)和Cobas® 6800 SARS-CoV-2检测(罗氏分子诊断,“罗氏”)。
收集了2020年3月23日至8月6日期间使用罗氏或赛沛检测对呼吸道样本进行的所有SARS-CoV-2 RT-PCR结果。如果OPT结果的患者符合以下三项标准中的至少一项,则被分类为“可能的COVID-19”:(i)有两次基因阳性的SARS-CoV-2 RT-PCR结果病史,(ii)检测到抗SARS-CoV-2抗体(IgG)或(iii)胸部计算机断层扫描(CT扫描)结果相符。
分别使用罗氏和赛沛检测进行了18,630次和1189次SARS-CoV-2 RT-PCR检测。在SARS-CoV-2 RT-PCR阳性结果中,293份样本(对应264名患者)为OPT(占阳性样本的11%)。在这些患者中,180名(68%)符合上述三项标准中的至少一项,被分类为可能的COVID-19。
68%的OPT结果患者被分类为可能的COVID-19,可能处于感染后期。血清学和影像学有助于确诊。